Nucleai ⚠ Under review

About

Headcount over time

Offices

Q&A

What is Nucleai's primary focus?

Nucleai is an AI-powered spatial biology company that analyzes tissue images to identify predictive biomarkers for precision oncology, supporting drug discovery and development.

When was Nucleai founded?

Nucleai was founded in July 2017.

Which investors participated in Nucleai's Series B funding round?

In March 2022, Nucleai raised a B Round of $33,000,000, with lead investors Section 32 and Sanofi Ventures.

What is the total amount of funding Nucleai has raised to date?

Nucleai has raised a total of $75,000,000.

How many employees does Nucleai currently have?

Nucleai currently has 65 employees, falling within the 51-200 employee bucket.

What was a recent partnership announced by Nucleai?

In June 2024, Nucleai and Proscia partnered to integrate predictive biomarker solutions.

Did Nucleai experience any layoffs recently?

In June 2024, Nucleai laid off 15% of its employees.

What was a strategic collaboration announced by Nucleai in April 2024?

In April 2024, Nucleai and GoPath Diagnostics announced a strategic collaboration to provide integrated AI-powered digital pathology solutions for clinical research and diagnostic applications.

Team · 12

Avi Veidman

Founder · CEO, Co-Founder

Lotan Chorev

Founder · Co-founder & VP R&D

Eliron Amir

Founder · Co-founder & COO

Dudi (David) Benayoun

COO

Aviv Levi

Director of Legal and Corporate Operations

Grainger Greene

Head of Product

Elad Amsalem

VP R&D

Ken Bloom, MD, FCAP

Head of Pathology

Hagar Sachs

Head of RA and QA

Ettai Markovits, MD, PhD

Director of Biomedical Research

Dani Zeevi

Director of Strategy

Byron Lawson

VP, Pharma BD & Strategic Partnerships

Sectors & technology

Highlights

Tags